Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2004-12-13
2009-10-20
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S178100
Reexamination Certificate
active
07605235
ABSTRACT:
Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.
REFERENCES:
patent: 5223427 (1993-06-01), Edgington et al.
patent: 5589173 (1996-12-01), O'Brien et al.
patent: 5726147 (1998-03-01), Ruf et al.
patent: 5766591 (1998-06-01), Brooks et al.
patent: 5986065 (1999-11-01), Wong et al.
patent: 6001978 (1999-12-01), Edgington et al.
patent: 6036955 (2000-03-01), Thorpe et al.
patent: 6238878 (2001-05-01), Jakobsen et al.
patent: 6274142 (2001-08-01), O'Brien et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6555319 (2003-04-01), Wong et al.
patent: 6677436 (2004-01-01), Sato et al.
patent: 6703494 (2004-03-01), Kirchhofer et al.
patent: 7235380 (2007-06-01), Joliffe et al.
patent: 0833911 (1996-06-01), None
patent: 1069185 (1999-02-01), None
patent: WO 88/07543 (1988-10-01), None
patent: WO 91/09968 (1991-07-01), None
patent: WO 94/05328 (1994-03-01), None
patent: WO 94/11029 (1994-05-01), None
patent: WO 96/40921 (1996-12-01), None
patent: WO 9640921 (1996-12-01), None
patent: WO 01/70984 (2001-09-01), None
patent: WO 01/24626 (2001-12-01), None
patent: WO/03/018771 (2003-03-01), None
patent: WO 03/029295 (2003-04-01), None
patent: WO 03037911 (2003-05-01), None
patent: WO 2004/039842 (2004-05-01), None
patent: WO 2004039842 (2004-05-01), None
patent: WO 2004094475 (2004-11-01), None
Rudikoff et al. Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
MacCallum et al. J. Mol. Biol. (1996) 262, 732-745.
Pascalis et al. The Journal of Immunology (2002) 169, 3076-3084.
Casset et al. (2003) BBRC 307, 198-205.
Vajdos et al. Journal of Molecular Biology. (2002) 320, 415-428.
Chen et al. J. Mol. Bio. (1999) 293, 865-881.
Wu et al. J. Mol. Biol. (1999) 294, 151-162.
Holm et al. Molecular Immunology, (2007) 44, 1075-1084.
Mueller et al. PNAS vol. 89 pp. 11832-11836, Dec. 1992.
Reff et al. (Critical Reviews in Oncology/Hematology, vol. 40, pp. 25-35, 2001).
Ruf, Wolfram et al, Purification, sequence and crystallization of an anti-tissue factor, Journal of Crystal Growth 122 (1992), 253-264.
Morrisey et al (1988), “Monoclonal Antibody analysis of purified and cell-associated tissue factor” Thrombosis Research 52:2.
Morrisey et al (1987) “Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade” Cell 50:129-135.
Owens et al, (1994)“The genetic engineering of monoclonal antibodies” Journal of Immunological Methods 168:149-165.
Ruf et al, (1991) “An anti-tissue factor monoclonal antibody which inhibits TF-Vlla complex is a potent anticoagulant in plasma” Thrombosis and Haemostasis 66:529-533.
Winter et al, (1993)“Humanized antibodies” Immunology Today 14:243.
Fiore, Martine et al, (1992) An Unusual Antibody that Blocks Tissue Factor/Factor Vlla Function by Inhibiting cleavage Only of Macromolecular Substrates Blood, vol. 80, No. 12, 3127-3134.
Ragni, Massimo et al, (1996) “Monoclonal Antibody Against Tissue Factor Shortens Tisue Plasminogen Activator LysisTime and Prevents Reocclusion in a Rabbit Model of Carotid Artery Thrombosis” Ciruclation vol. 93, No. 10, 1913-1918.
Ardissino, diego et al (2001) “Thrombogenic potential of human coronary atheroscierotic plaques” Blood vol. 98, No. 9, 2726-2729.
Presta, Leonard et al (2001) “Generation of a Humanized, High affinity Anti-Tissue Factor Antibody for Use as Novel Antithrombotic Therapeutic” Thromb Haemost 2001; 85; 379-89.
Carson, Steven et al (1987) “An Inhibitory Monoclonal Antibody Against Human Tissue Factor” Blood vol. 70, No. 2, 490-493.
Paborsky, Lisa et al (1990) “Mammalian cell transient expression of tissue factor for the production of antigen” Protein Engineering vol. 3, No. 6, 547-553.
Tanaka, H et al (1985) “Purification of Glycosylated Apoprotein of Tissue Factor Brain and Inhibition of its Procoagulant Activity by a Specific Antibody” Thrombosis Research 40:745-756.
Kirchhofer, Daniel et al, (2000) “Epitope Location on Tissue Factor Determines the Anticoagulant Potency of Monoclonal Anti-tissue Factor Antibodies,” Thromb Haemost 2000, 84:1072-81.
Huang, Mingdong et al (1998) “The Mechanism of an Inhibitory Antibody on TF-initiated Blood Coagulation Revealed by the Crystal Structures of Human Tissue Factor, Fab 5G9 and TF 5G9 Complex.” J. Mol. Biol. 275, 873-894.
Chen, Jiang et al, (2001) Tissue Factor—A Receptor Involved in the Control of Cellular Properties, Including Angiogenesis Thromb Haemost 2001, 86:334-345.
Rao, Chilukuri N. et al (2001) “Expression of Tissue Factor Pathway Inhibitor 2 Inversely Correlates during the Progression of Human Gilomas” Clinical Cancer Research vol. 7, 570-576.
Mechtcheriakova, Diana et al (2001) “Specificity, diversity, and convergence in VEGF and TNG—signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells.” FASEB J. 2001, 15: 230-242.
Shen, Ben Quan et al (Feb. 16, 2001) “Vascular Endothelial growth Factor KDR Receptor Signaling Potentiates Tumor Necrosis Factor-induced Tissue Factor Expression in Endothelial Cells.” The Journal of Biological Chemistry. vol. 276, No. 7, 5281-5286.
Hu et al, (2001) “Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer.” Department of Molecular Biophysics and Biochemistry, Yale University, vol. 98, No. 21, 12180-12185.
Nilsson et al; (2001) “Targeted Delivery of Tissue Factor to the ED-B Domain of Fibronectin, a Marker of Angiogenesis, Mediates the Infaarction of Solid tumors in Mice.” Cancer Research, vol. 61, 711-716.
Hu et al, (1999) “Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model.” Proc. National Acad. Sci. vol. 96, pp. 8161-8166, USA.
Ran et al, (1998) “Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature.” Cancer Research, vol. 58, Issue 20, p. 4646-4653, USA.
Huang et al, (1997) “Tumor Infarction in Mice By Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature.” Science vol. 275, pp. 547-550.
Amirkhosravi et al, (2002), “Tissue Factor Pathway Inhibitor Reduces Experimental Lung Metastasis of B16Melano a. ”Throm Haemost, vol. 87, 930-936.
Palumbo et al, (2000), Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells, Blood, vol. 96 (10) 3302-3309.
Hembrough et al (2003) “Tissue Factor/Factor Vlla Inhibitors block angiogenesis and Tumor Growth Through A Nonhemostatic Mechanism,” Cancer Reseach, vol. 63, pp. 2997-3000.
Bromberg et al (1995), “Tissue Factor promotes melanoma metastasis by a pthway independent of blood coagulation.” Proc. Natl Acad. Sci., vol. 92, pp. 8205-8209, USA.
Bazan, J. Fernando (1990) “Structural design and molecular evolution of a cytokine receptor superfamily” Proc. Natl Acad. Sci, USA., vol. 87, pp. 6934-6938, Biochemistry.
Ruf et al, (1999), “Tissue Factor Signaling” Thrombosis and Haemostasis—82 (2) 175-182, The Scripps Research Institute, USA.
Versteeg et al, (2001) “The Pleiotropic Effects of Tissue Factor: A Possible Role for Factor Vlla-induced Intracellular Sign
Anderson G. Mark
Cai Ann
Naso Michael
Ngo Cam
Scallon Bernard
Centocor, Inc.
Dow Kenneth J.
Helms Larry R.
Natarajan Meera
LandOfFree
Anti-tissue factor antibodies and compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-tissue factor antibodies and compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-tissue factor antibodies and compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4081227